C4 Therapeutics, Inc. (CCCC) Financial Statements
C4 Therapeutics, Inc. (CCCC) reported trailing twelve-month revenue of $35.0M (up 2.3% year on year) and net income of -$101.4M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$85.4M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CCCCC4 Therapeutics, Inc.Follow CCCC — free
—
Price chart with a free account
- Market cap
- 376.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Revenue | 31.1 | 20.8 | 35.6 | 35.9 | 35.0 | |
| Gross profit | — | — | 33.1 | 25.2 | — | |
| Research & development | 117.8 | 117.7 | 110.6 | 104.2 | 100.0 | |
| Operating income | -129.5 | -139.0 | -119.6 | -115.2 | -111.8 | |
| Pre-tax income | -128.2 | -131.2 | -105.2 | -104.9 | -101.3 | |
| Income tax | 0.0 | 1.3 | 0.1 | 0.1 | 0.1 | |
| Net income | -128.2 | -132.5 | -105.3 | -105.0 | -101.4 | |
| Diluted EPS ($) | -2.62 | -2.67 | -1.52 | -1.27 | -0.78 | |
| Diluted shares (mn) | 48.9 | 49.6 | 69.4 | 82.9 | — |
USD millions · SEC XBRL
C4 Therapeutics, Inc. — questions
- What is C4 Therapeutics, Inc.'s revenue?
- $35.0M over the twelve months to 2026-06-30, up 2.3% year on year, from its 10-Q and 10-K filings.
- What is C4 Therapeutics, Inc.'s net income?
- -$101.4M over the twelve months to 2026-06-30.
- What is C4 Therapeutics, Inc.'s free cash flow?
- -$85.4M over the twelve months to 2026-06-30.
- What are C4 Therapeutics, Inc.'s diluted earnings per share?
- $-0.78 over the twelve months to 2026-06-30.
Every figure on this page comes from C4 Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.